List view / Grid view
26 January 2021 | By Hannah Balfour (Drug Target Review)
The patient-derived model of non-alcoholic fatty liver disease (NAFLD) accurately reproduced the complex human metabolic pathways involved in the development of the disease.
2 June 2020 | By Hannah Balfour (Drug Target Review)
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin, increased glucose tolerance and lean body mass in a murine model of non-alcoholic fatty liver disease (NAFLD).
18 May 2018 | By Dr Zara Kassam (Drug Target Review)
Researchers have identified a key in the road for the way the liver deals with carbohydrates, fats and protein...
17 March 2016 | By James Adjaye (Heinrich-Heine-University), Marie-Ann Kawala (Heinrich-Heine-University), Nina Graffmann (Heinrich-Heine-University), Wasco Wruck (Heinrich-Heine-University)
Non-alcoholic fatty liver disease (NAFLD), a consequence of sedentary life styles and high fat diets, has an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms within genes such as PNPLA3, TM6SF2, APOC3, NCAN and PPP1R3B correlate…
8 October 2021 | By Anna Begley (Drug Target Review)
Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
21 September 2021 | By Anna Begley (Drug Target Review)
DNA methylation at specific genomic sites was found to correlate with non-fatty liver disease and could be used to diagnose severity.
21 April 2021 | By Victoria Rees (Drug Target Review)
Researchers have successfully used label-free near-infrared hyperspectral imaging for mouse livers, which could aid in the diagnosis of NAFLD.
31 March 2021 | By Victoria Rees (Drug Target Review)
A class of lipids – or fatty acids – found in the retina of the eye play an important role in maintaining vision. Victoria Rees, Deputy Editor of Drug Target Review, spoke with Dr Paul Bernstein from the Moran Eye Center at the University of Utah, US, to discover how…
11 March 2021 | By Victoria Rees (Drug Target Review)
A liver-on-a-chip model has been developed to more fully represent the natural progression of NAFLD than previous models.
27 January 2020 | By Hannah Balfour (Drug Target Review)
A study identifying transcription factor differences in the hepatic stellate cells of mice with liver fibrosis named PPARγ as a potential target for the condition’s regression and scar resolution therapies.
23 January 2020 | By Victoria Rees (Drug Target Review)
Mice given a novel drug that targets a key gene involved in lipid and glucose metabolism were able to tolerate a high-fat diet regimen without developing significant liver damage.
30 August 2019 | By Rachael Harper (Drug Target Review)
New lab on a chip technology has been developed to evaluate the effects of different drivers of NAFLD on liver cells.
6 August 2019 | By Rachael Harper (Drug Target Review)
The first genetically modified mini human livers have been grown in a laboratory, to emulate liver disease progression and test therapeutics.
3 August 2018 | By Drug Target Review
Aortic atherosclerotic plaque inflammation may contribute to the progression of non-alcoholic fatty liver disease to liver fibrosis...
2 August 2018 | By Dr Zara Kassam (Drug Target Review)
In a series of experiments, researchers have used an experimental compound to successfully reverse hair loss, hair whitening and skin inflammation...
